Ani Pharmaceuticals (ANIP) Change in Accured Expenses (2016 - 2018)
Ani Pharmaceuticals' Change in Accured Expenses history spans 9 years, with the latest figure at $1.0 million for Q3 2018.
- On a quarterly basis, Change in Accured Expenses fell 43.14% to $1.0 million in Q3 2018 year-over-year; TTM through Sep 2018 was $174000.0, a 74.0% increase, with the full-year FY2017 number at $644000.0, down 31.49% from a year prior.
- Change in Accured Expenses hit $1.0 million in Q3 2018 for Ani Pharmaceuticals, up from -$749000.0 in the prior quarter.
- Over the last five years, Change in Accured Expenses for ANIP hit a ceiling of $1.8 million in Q3 2017 and a floor of -$1.9 million in Q4 2015.
- Historically, Change in Accured Expenses has averaged $171473.7 across 5 years, with a median of $143000.0 in 2014.
- Biggest five-year swings in Change in Accured Expenses: crashed 523.08% in 2015 and later skyrocketed 45125.0% in 2017.
- Tracing ANIP's Change in Accured Expenses over 5 years: stood at -$630000.0 in 2014, then tumbled by 198.57% to -$1.9 million in 2015, then increased by 8.88% to -$1.7 million in 2016, then soared by 31.74% to -$1.2 million in 2017, then soared by 187.52% to $1.0 million in 2018.
- Business Quant data shows Change in Accured Expenses for ANIP at $1.0 million in Q3 2018, -$749000.0 in Q2 2018, and $1.1 million in Q1 2018.